By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

Novartis invests EUR 100 million

Sandoz plant in Schaftenau © Novartis

The subsidiary will be expanded to include, amongst other things, an integrated cell culture production, creating 190 new jobs. There originator biologicals from Novartis and biosimilars from Sandoz will be produced for the global market.

“Originator biologicals and biosimilars are the future of modern medicine. Novartis is a global leader in production and development in this field. Thanks to this investment we are even more pleased with the fact that the future of medicine will take place in Austria”, says Ard van der Meij, Country President of Novartis Austria.

Austrian quality for the world market

The Schaftenau plant is of major importance for Novelis due to the production of originator biologicals and biosimilars. This includes a focus product from Novartis pharmaceuticals for the therapy of psoriasis, psoriasis arthritis and Bektherev’s disease and two cost efficient Sandoz biosimilars. One of them is for the treatment of certain forms of blood cancer and immunological diseases, the other for the treatment of rheumatoid arthritis and other rheumatic illnesses. In 2014 and 2015, a global microparticle technology center and a state-of-the-art biologicals production for ready-to-fill syringes were open, and the production facilities were continuously expanded.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • BIOMEDevice Boston 2020

    16. - 17.09.2020, Boston, USA

  • Festival of Enterprise London Event

    21. / 22.10.2020, London, UK

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Top Score for Lockdown – Austria convinces in current Deloitte entrepreneur survey with well thought out Covid-19 measures

Austria convinces in current Deloitte survey and gets top score for well thought out Covid-19 measures.

Concerning Facebook and LinkedIn: Austrian companies in the social media jungle

A growing number of companies are relying on social media to inform customers, open up new target groups and identify suitable employees. Firms are increasingly investing in Facebook and other social media as each year passes, However, at the same time the continuous further development and establishment of networks are also leading to uncertainties about the right way of handling these platforms.

More news All blog posts